Loring Wolcott & Coolidge Fiduciary Advisors’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | $711K | Hold |
|
|||||
|
2025
Q2 | $500K | Hold |
|
|||||
|
2025
Q1 | $371K | Hold |
|
|||||
|
2024
Q4 | $424K | Sell |
|
|||||
|
2024
Q3 | $526K | Sell |
|
|||||
|
2024
Q2 | $476K | Hold |
|
|||||
|
2024
Q1 | $278K | Hold |
|
|||||
|
2023
Q4 | $329K | Hold |
|
|||||
|
2023
Q3 | $308K | Sell |
|
|||||
|
2023
Q2 | $373K | Hold |
|
|||||
|
2023
Q1 | $394K | Hold |
|
|||||
|
2022
Q4 | $467K | Hold |
|
|||||
|
2022
Q3 | $393K | Hold |
|
|||||
|
2022
Q2 | $287K | Sell |
|
|||||
|
2022
Q1 | $331K | Hold |
|
|||||
|
2021
Q4 | $343K | Hold |
|
|||||
|
2021
Q3 | $382K | Sell |
|
|||||
|
2021
Q2 | $346K | Sell |
|
|||||
|
2021
Q1 | $289K | Buy |
|
|||||
|
2020
Q4 | $263K | Hold |
|
|||||
|
2020
Q3 | $295K | Hold |
|
|||||
|
2020
Q2 | $300K | Hold |
|
|||||
|
2020
Q1 | $220K | Hold |
|
|||||
|
2019
Q4 | $233K | Hold |
|
|||||
|
2019
Q3 | $163K | Hold |
|
|||||
|
2019
Q2 | $147K | Hold |
|
|||||
|
2019
Q1 | $189K | Hold |
|
|||||
|
2018
Q4 | $148K | Sell |
|
|||||
|
2018
Q3 | $703K | Hold |
|
|||||
|
2018
Q2 | $791K | Hold |
|
|||||
|
2018
Q1 | $956K | Hold |
|
|||||
|
2017
Q4 | $1.02M | Sell |
|
|||||
|
2017
Q3 | $972K | Hold |
|
|||||
|
2017
Q2 | $685K | Hold |
|
|||||
|
2017
Q1 | $424K | Hold |
|
|||||
|
2016
Q4 | $310K | Hold |
|
|||||
|
2016
Q3 | $561K | Sell |
|
|||||
|
2016
Q2 | $477K | Hold |
|
|||||
|
2016
Q1 | $539K | Hold |
|
|||||
|
2015
Q4 | $809K | Sell |
|
|||||
|
2015
Q3 | $1.53M | Hold |
|
|||||
|
2015
Q2 | $1.53M | Sell |
|
|||||
|
2015
Q1 | $1.58M | Sell |
|
|||||
|
2014
Q4 | $1.57M | Hold |
|
|||||
|
2014
Q3 | $1.26M | Hold |
|
|||||
|
2014
Q2 | $1.02M | Sell |
|
|||||
|
2014
Q1 | $1.09M | Sell |
|
|||||
|
2013
Q4 | $1.16M | Sell |
|
|||||
|
2013
Q3 | $1.37M | Sell |
|
|||||
|
2013
Q2 | $722K | Buy |
|